Navigation Links
Fine tuning cardiac ablation could lead to quicker results for patients with arrhythmias
Date:7/24/2012

University of Michigan heart researchers are shedding light on a safer method for steadying an abnormal heart rhythm that prevents collateral damage to healthy cells.

Irregular heart rhythms, or arrhythmias, set the stage for a common, debilitating disorder called atrial fibrillation that puts adults as young as age 40 at risk for fatigue, fainting, cardiac arrest, and even death. Medications can help, but doctors also use catheter ablation in which electrical impulses are delivered to a region of the heart to disrupt the arrhythmia.

However, studies show half of patients require more than one ablation to see results. In a laboratory study, the U-M used photodynamic therapy, a technique long used in cancer research, to disrupt the specific cells causing the arrhythmia.

The study suggests cell-specific cardiac ablation could help patients avoid complications, and get closer to an arrhythmia-free life without having to undergo repeat hospital visits.

Chemists in the U-M Department of Chemistry and electrophysiologists at the U-M Center for Arrhythmia Research collaborated on the study that will require further examination before it is available in the hospital setting.

"This cell-selective therapy may represent an innovative concept to overcome some of the current limitations of cardiac ablation," says lead study author Uma Mahesh Avula, M.D., research fellow at the U-M Center for Arrhythmia Research.

The study was published online ahead of print in the September issue of the Journal of Heart Rhythm.

The heart consists of different types of cells such as myocytes, fibroblast, adiopocytes and purkinje fibers, which are all needed for normal cardiac activity.

The new study is the first of its kind to use photodynamic therapy and nanotechnology to ablate only the cardiac myocytes responsible for arrhythmias. In current ablative techniques, all cardiac cells receive ablative energy, which can lead to complications such as puncturing the heart muscle, bleeding or stroke.

"Current ablation techniques are severely limited by its non-specific nature of cellular damage. Besides this lack of cellular discrimination markedly increases the required energy amounts and prolongs procedure times, all of which reduces overall ablation results," Avula says.

Catheter ablation has emerged as an important treatment option that requires careful assessment, planning and execution for optimal success rates. Advances over the past 20 years have made the treatment safer, but it remains highly complex.

"Approaches that could simplify and shorten the procedure may contribute to more patients being treated," Avula says.

Rather than radiofrequency energy, the most common type used in cardiac ablation, the U-M team introduces the use of PDT in cardiac electrophysiology to target specific cell types. Targeted PDT, which was pioneered in the labs of study senior author U-M chemist and engineer Raoul Kopelman, Ph.D., is extensively used in cancer research for selectively killing cancerous cells.

The disruption induced by PDT is confined to cells that have been photosensitized, while adjacent non-photosensitized cells are unaffected.

"We think this approach will decrease the extent of unwanted cell injury, inflammation, and ablation-related tissue damage, and pave a way for the development of more effective therapies for cardiac arrhythmias," says study senior author Jrme Kalifa, M.D., Ph.D., assistant professor of internal medicine at the U-M Health System.


'/>"/>

Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Are cardiac risk factors linked to less blood flow to the brain?
2. Wake Forest Baptist study suggests Tasers dont cause cardiac complications
3. Study Spots Early Warning Signal for Sudden Cardiac Death
4. Study: Heart damage after chemo linked to stress in cardiac cells
5. People With HIV at Higher Odds of Sudden Cardiac Death
6. Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study
7. Erectile dysfunction drug may benefit cardiac function in young patients with heart defects
8. SMART heart eases heart ache, targets cardiac patients emotional well-being
9. Many Medicaid Patients Skip Drugs That Could Prevent Heart Trouble
10. A good nights sleep could keep you out of a nursing home
11. Mouse With Human-Like Immune System Could Advance AIDS Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fine tuning cardiac ablation could lead to quicker results for patients with arrhythmias
(Date:9/25/2017)... Angeles, CA (PRWEB) , ... September 25, 2017 , ... ... of a full-time office in downtown Los Angeles, to service existing clients in the ... surrounding areas. , “We are seeing an ever-increasing amount of business demand west of ...
(Date:9/24/2017)... ... , ... Bhowanie Benimadhu’s new book “ Our Creative World: Our Created Life ... answers in both Eastern and Western religious traditions and spirituality such as Hinduism ... of humankind for the past thousands of years and still are,” Benimadhu says. “By ...
(Date:9/24/2017)... ... September 24, 2017 , ... The Tuscany Resort on Grace Bay in ... Provo's premier boutique resorts, is planning on re-opening the resort on October 1st. ... Irma and more recently Hurricane Maria, and the staff and landscaping crews were fast ...
(Date:9/24/2017)... ... ... “Star of Bethlehem Study”: is a thought-provoking essay focusing on the most ... Duane Engdahl, an investigator who had has a long and eventful career in science ... a thought-provoking essay an event so significant that it is referred to as the ...
(Date:9/23/2017)... ... 23, 2017 , ... “You Can't Win Them All”: the story of an ... and on the ice changed the lives of young athletes. “You Can't Win ... born and educated in Schreiber, a small town in Northern Ontario, Canada. He ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
(Date:9/1/2017)... -- Bayer will present the latest research from across its growing ... 2017 Congress, September 8-12 in Madrid, Spain ... data on Bayer,s marketed portfolio and late-stage compounds as well ... "We value the opportunity to meet ... ESMO," said Carsten Brunn , Head of Pharmaceuticals, Americas ...
Breaking Medicine Technology: